Neeraj Agarwal, MD | Authors


Apalutamide Plus ADT Leads to Survival Benefit in mCSPC

January 07, 2020

Neeraj Agarwal, MD, discusses the results from the randomized phase III TITAN trial, which enrolled over 1,000 patients with newly diagnosed metastatic castration-sensitive prostate cancer and randomized them to either androgen deprivation therapy plus the novel androgen receptor inhibitor apalutamide or ADT alone.